F. Stephen Hodi

161.5k citations

517 papers · 44.0k indexed · 29 hit papers · h-index 101

Impact in

Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Lung Cancer Research Studies
Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 443
- Cancer Immunotherapy and Biomarkers 360
- CAR-T cell therapy research 206
- Cutaneous Melanoma Detection and Management 41
- Colorectal Cancer Treatments and Studies 38
Immunology 197
- Immunotherapy and Immune Responses 158

Co-authors: Jedd D. Wolchok Jeffrey S. Weber Patrick A. Ott Mizuki Nishino Caroline Robert Omid Hamid Nikhil H. Ramaiya Anita Giobbie‐Hurder
Journals: Journal of Clinical Oncology (162 papers)Annals of Oncology (41 papers)Clinical Cancer Research (37 papers)Cancer Immunology Research (31 papers)Journal for ImmunoTherapy of Cancer (29 papers)
Partner nations: United States France Germany

In The Last Decade

F. Stephen Hodi

500 papers receiving 43.4k citations

Hit Papers

15 papers align trajectories log scale

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors 2021 · 257 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Clinical Cancer Research
2021 Clinical Cancer Research
2020 Cell
2019 Annals of Oncology
2019 JAMA Oncology
2019 Clinical Cancer Research
2018 Endocrine Reviews
2018 The Lancet Oncology
2018 Science Translational Medicine
2017 The Lancet Oncology
2017 Nature Reviews Clinical Oncology
2017 Journal of Clinical Oncology
2017 Cancer Immunology Research
2017 JAMA Oncology
2017 Cell
2016 Journal for ImmunoTherapy of Cancer
2016 Kidney International
2016 JAMA Oncology
2016 Clinical Cancer Research
2016 Clinical Cancer Research
2016 European Journal of Cancer
2015 Journal of Clinical Oncology
2013 Clinical Cancer Research
2013 Annals of the New York Academy of Sciences
2012 Clinical Cancer Research
2012 The Lancet Oncology
2009 Clinical Cancer Research
2008 Proceedings of the National Academy of Sciences
2003 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by F. Stephen Hodi

Since Specialization

Citations

This map shows the geographic impact of F. Stephen Hodi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Stephen Hodi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Stephen Hodi more than expected).

Fields of papers citing papers by F. Stephen Hodi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Stephen Hodi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Stephen Hodi. The network helps show where F. Stephen Hodi may publish in the future.

Co-authors

The 25 scholars most cited alongside F. Stephen Hodi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with F. Stephen Hodi Line = papers co-authored together F. Stephen Hodi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma Cancer Research Communications ·Elizabeth I. Buchbinder, Justine V. Cohen, Giuseppe Tarantino, Christine G. Lian, David Liu, Rizwan Haq, F. Stephen Hodi, Donald P. Lawrence, Anita Giobbie‐Hurder, Deborah Knoerzer, Ryan J. Sullivan	2024	7
2	Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma. Journal of Clinical Oncology ·Jeffrey S. Weber, Amrutesh S. Puranik, Teruyuki Mitzutani, Tomoaki Muramatsu, Judith D. Goldberg, Janice M. Mehnert, Xiaochun Li, Benjamin Levinson, Omid Hamid, Inderjit Mehmi, Mark B. Faries, F. Stephen Hodi, Elizabeth I. Buchbinder, Patrick A. Ott, Sofia Bajwa, Perla Arriola, Naika Legros, Ryan J. Sullivan	2024	10
3	Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071 Molecular Cancer Therapeutics ·Sophie Piperno‐Neumann, James Larkin, Richard D. Carvajal, Jason J. Luke, Gary K. Schwartz, F. Stephen Hodi, Marie‐Paule Sablin, Alexander N. Shoushtari, Sebastian Szpakowski, Niladri Roy Chowdhury, A. Rose Brannon, Thiruvamoor Ramkumar, Leanne de Koning, Adnan Derti, (unknown), Padmaja Yerramilli-Rao, Ellen Kapiteijn	2020	41
4	Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis Cancer ·Michael Li, Jordan Sack, Osama E. Rahma, F. Stephen Hodi, Stephen D. Zucker, Shilpa Grover	2020	40
5	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab Clinical Cancer Research ·Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi	2019	58
6	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients Cancer Immunology Research ·Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark M. Awad, Patrick A. Ott, Raphael Brandão Moreira, Fabio A.B. Schutz, Joaquim Bellmunt, Guru Sonpavde, F. Stephen Hodi, Toni K. Choueiri Hit paper breakdown →	2017	369
7	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma Journal of Clinical Oncology ·Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard W. Joseph, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Jin Zhang, James R. Anderson, Scott J. Diede, Scot Ebbinghaus, F. Stephen Hodi	2017	336
8	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody Clinical Cancer Research ·Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David F. McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion‐Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure–Kunkel, Suba Krishnan, Holbrook E. Kohrt, Mario Sznol, Ronald Levy Hit paper breakdown →	2016	281
9	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma Cancer Immunology Research ·Xinqi Wu, Anita Giobbie‐Hurder, Xiaoyun Liao, Donald P. Lawrence, David F. McDermott, Jun Zhou, Scott J. Rodig, F. Stephen Hodi	2016	76
10	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes Cancer Immunology Research ·Vishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, Nicole G. Chau, Robert I. Haddad, Mariano Severgnini, Peter S. Hammerman, Adel K. El‐Naggar, Gordon J. Freeman, F. Stephen Hodi, Scott J. Rodig, Glenn Dranoff, Jonathan D. Schoenfeld	2016	77
11	An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma Clinical Cancer Research ·Danny N. Khalil, Michael A. Postow, Nageatte Ibrahim, Dale L. Ludwig, Jan Cosaert, Siva Rama Prasad Kambhampati, Shande Tang, Dmitri Grebennik, John Kauh, Heinz‐Josef Lenz, Keith T. Flaherty, F. Stephen Hodi, Donald P. Lawrence, Jedd D. Wolchok	2016	19
12	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition Clinical Cancer Research ·Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, René González, Jose Lutzky, Steven O’Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil H. Ramaiya, Anita Giobbie‐Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi	2015	97
13	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma Cancer Immunology Research ·Marcella Callea, Laurence Albigès, Mamta Gupta, Su–Chun Cheng, Elizabeth M. Genega, André P. Fay, Jiaxi Song, Ingrid Carvo, Rupal S. Bhatt, Michael B. Atkins, F. Stephen Hodi, Toni K. Choueiri, David F. McDermott, Gordon J. Freeman, Sabina Signoretti	2015	266
14	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells Cancer Immunology Research ·Kathleen M. Mahoney, Heather H. Sun, Xiaoyun Liao, Ping Hua, Marcella Callea, Edward Greenfield, F. Stephen Hodi, Arlene H. Sharpe, Sabina Signoretti, Scott J. Rodig, Gordon J. Freeman	2015	103
15	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model Cancer Immunology Research ·David A. Reardon, Prafulla C. Gokhale, Sarah R. Klein, Keith L. Ligon, Scott J. Rodig, Shakti Ramkissoon, Kristen L. Jones, Amy Saur Conway, Xiaoyun Liao, Jun Zhou, Patrick Y. Wen, Annick D. Van den Abbeele, F. Stephen Hodi, Lei Qin, Nancy E. Kohl, Arlene H. Sharpe, Glenn Dranoff, Gordon J. Freeman	2015	302
16	CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients Clinical Cancer Research ·Patrick A. Ott, F. Stephen Hodi, Caroline Robert Hit paper breakdown →	2013	557
17	Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways Molecular Cancer Therapeutics ·Xinqi Wu, Jingjing Li, Mei‐Jun Zhu, Jonathan A. Fletcher, F. Stephen Hodi	2012	71
18	The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition Clinical Cancer Research ·Xiaofeng Jiang, Jun Zhou, Anita Giobbie‐Hurder, Jennifer A. Wargo, F. Stephen Hodi	2012	406
19	Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis Cancer Research ·Jonathan D. Schoenfeld, Masahisa Jinushi, Yukoh Nakazaki, Daniel Wiener, Joosang Park, Robert J. Soiffer, Donna Neuberg, Martín C. Mihm, F. Stephen Hodi, Glenn Dranoff	2010	64
20	Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma Cancer Research ·William M. Lin, Alissa C. Baker, Rameen Beroukhim, Wendy Winckler, Whei Feng, Jennifer M. Marmion, Elisabeth Laine, Heidi Greulich, Hsiuyi Tseng, Casey Gates, F. Stephen Hodi, Glenn Dranoff, William R. Sellers, Roman K. Thomas, Matthew Meyerson, Todd R. Golub, Reinhard Dummer, Meenhard Herlyn, Gad Getz, Levi A. Garraway	2008	215

About F. Stephen Hodi

F. Stephen Hodi is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology, having authored 517 papers that have together received 44.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (360 papers), CAR-T cell therapy research (206 papers), Immunotherapy and Immune Responses (158 papers), Melanoma and MAPK Pathways (107 papers), Cutaneous Melanoma Detection and Management (41 papers), Colorectal Cancer Treatments and Studies (38 papers), Cancer Genomics and Diagnostics (35 papers) and Lung Cancer Treatments and Mutations (31 papers). The work is most often cited by research in Oncology (34.2k citations), Immunology (16.7k citations), Pulmonary and Respiratory Medicine (9.8k citations), Cancer Research (3.4k citations) and Genetics (2.1k citations). F. Stephen Hodi has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Jedd D. Wolchok, Jeffrey S. Weber, Patrick A. Ott, Mizuki Nishino, Caroline Robert, Omid Hamid, Nikhil H. Ramaiya, Anita Giobbie‐Hurder, Hiroto Hatabu and Dirk Schadendorf. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Cancer Immunology Research and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact